Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 20, Issue 2-3, 2005, Pages 120-132

  Brodaty, Henry ^a,e   Corey Bloom, Jody ^b   Potocnik, Felix C V ^c   Truyen, Luc ^d   Gold, Michael ^d   Damaraju, Chandrasekhar Rao V ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Stikland Hospital   (South Africa)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Galantamine; Nicotinic receptors; Prolonged release formulation

Indexed keywords

GALANTAMINE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CAREGIVER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; ECG ABNORMALITY; FALLING; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INJURY; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROPSYCHIATRY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BEHAVIOR; CHOLINESTERASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 23944516534     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086613     Document Type: Article

References (29)

1. Alzheimer's Disease International: Global impact of dementia. Alzheimer Dis Int, 2002; available at: http://www.alz.co.uk/global/.
2. Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
3. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A: Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024-1036.
4. Geerts H, Finkel L, Carr R, Spiros A: Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy. J Neural Trans 2002;62(suppl):203-216.
5. Doggrell SA, Evans S: Treatment of dementia with neurotransmission modulation. Expert Opin Investig Drugs 2003;12:1633-1654.
6. Bonner LT, Peskind ER: Pharmacologic treatments of dementia. Med Clin North Am 2002;86:657-674.
7. Trinh NH, Hoblyn J, Mohanty S, Yaffe K: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-216.
8. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2001;4:CD001747.
9. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
10. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268.
11. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000;321:1445-1449.
12. Wilkinson D, Murray J: Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:852-857.
13. Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G: Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 2003;25:1806-1825.
14. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342.
15. Jonsson L: Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. Pharmacoeconomics 2003;21:1025-1037.
16. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
17. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22-S32.
18. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39.
19. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
20. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research: Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; April 1996.
21. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D: Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-595.
22. Boothby H, Mann AH, Barker A: Factors determining interrater agreement with rating global change in dementia: the CIBIC-plus. Int J Geriatr Psychiatry 1995;10:1037-1045.
23. Connell CM, Janevic MR, Gallant MP: The costs of caring: impact of dementia on family caregivers. J Geriatr Psychiatry Neurol 2001; 14:179-187.
24. Veitch C, Hollins J, Worley P, Mitchell G: General practice research. Problems and solutions in participant recruitment and retention. Aust Fam Physician 2001;30:399-406.
25. Ranelli PL, Aversa SL: Medication-related stressors among family caregivers. Am J Hosp Pharm 1994;51:75-79.
26. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
27. Dezii CM, Kawabata H, Tran M: Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95:68-71.
28. Boucher L, Renvall MJ, Jackson JE: Cognitively impaired spouses as primary caregivers for demented elderly people. J Am Geriatr Soc 1996;44:828-831.
29. Yamada H, Sugiyama T, Ashida T, Ohwaki H, Fujii J: Medication management skill and regimen compliance are deteriorated in the elderly even without obvious dementia. Yakugaku Zasshi 2001;121:187-190.